• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃索美拉唑和泮托拉唑的抑酸作用比较及其与药代动力学和 CYP2C19 多态性的关系。

A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.

机构信息

Central Hospital Pharmacy and Haga Teaching Hospital, Den Haag, The Netherlands.

出版信息

Aliment Pharmacol Ther. 2010 Jan;31(1):150-9. doi: 10.1111/j.1365-2036.2009.04150.x.

DOI:10.1111/j.1365-2036.2009.04150.x
PMID:19785625
Abstract

BACKGROUND

Esomeprazole and pantoprazole are metabolized in the liver and the polymorphic CYP2C19 enzyme is involved in that process. This genetic polymorphism determines fast (70% of Caucasians), intermediate (25-30% of Caucasians) and slow (2-5% of Caucasians) metabolism of PPIs.

AIM

To compare the acid-inhibitory effects of esomeprazole 40 mg and pantoprazole 40 mg at 4, 24 and 120 h after oral administration in relation to CYP2C19 genotype and pharmacokinetics.

METHODS

CYP2C19*2, *3, *4, *5 and *17 genotypes were determined in healthy Helicobacter pylori-negative Caucasian subjects. 7 wt/wt, 7 wt/*2, 2 wt/*17, 2 *2/*17 and 1 *2/*2 were included in a randomized investigator-blinded cross-over study with esomeprazole 40 mg and pantoprazole 40 mg. Intragastric 24-h pH-monitoring was performed on days 0, 1 and 5 of oral dosing.

RESULTS

A total of 19 subjects (mean age 24 years, 7 male) completed the study. At day 1 and 5, acid-inhibition with esomeprazole was significantly greater and faster than with pantoprazole. Differences in acid-inhibition and pharmacokinetics between wt/wt and wt/*2 genotype were significant for pantoprazole at day 1 and 5.

CONCLUSIONS

Esomeprazole provides acid-inhibition faster than and superior to pantoprazole after single and repeated administration. The acid-inhibitory effect and the kinetics of pantoprazole are influenced by CYP2C19 genotype.

摘要

背景

埃索美拉唑和泮托拉唑在肝脏中代谢,多态性 CYP2C19 酶参与该过程。这种遗传多态性决定了质子泵抑制剂(PPIs)的快速(70%的白种人)、中间(25-30%的白种人)和缓慢(2-5%的白种人)代谢。

目的

比较埃索美拉唑 40mg 和泮托拉唑 40mg 在口服后 4、24 和 120 小时的抑酸作用与 CYP2C19 基因型和药代动力学的关系。

方法

在健康的幽门螺杆菌阴性白种人受试者中确定 CYP2C19*2、*3、*4、5 和17 基因型。7 名 wt/wt、7 名 wt/*2、2 名 wt/17、2 名2/17 和 1 名2/*2 被纳入一项随机、研究者设盲的交叉研究,分别给予埃索美拉唑 40mg 和泮托拉唑 40mg。在口服给药的第 0、1 和 5 天进行胃内 24 小时 pH 监测。

结果

共有 19 名受试者(平均年龄 24 岁,7 名男性)完成了这项研究。在第 1 天和第 5 天,埃索美拉唑的抑酸作用明显大于泮托拉唑,且起效更快。在第 1 天和第 5 天,wt/wt 和 wt/*2 基因型之间的抑酸作用和药代动力学差异在泮托拉唑中具有统计学意义。

结论

埃索美拉唑单次和重复给药后的抑酸作用快于并优于泮托拉唑。泮托拉唑的抑酸作用和动力学受 CYP2C19 基因型的影响。

相似文献

1
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism.埃索美拉唑和泮托拉唑的抑酸作用比较及其与药代动力学和 CYP2C19 多态性的关系。
Aliment Pharmacol Ther. 2010 Jan;31(1):150-9. doi: 10.1111/j.1365-2036.2009.04150.x.
2
A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.埃索美拉唑和雷贝拉唑的抑酸作用比较与药代动力学和 CYP2C19 多态性的关系。
Aliment Pharmacol Ther. 2012 Apr;35(7):810-8. doi: 10.1111/j.1365-2036.2012.05014.x. Epub 2012 Feb 13.
3
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.CYP2C19*2和*17突变对高加索人群中质子泵抑制剂药效学和药代动力学的影响。
Br J Clin Pharmacol. 2008 May;65(5):752-60. doi: 10.1111/j.1365-2125.2007.03094.x. Epub 2008 Jan 30.
4
Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.健康中国志愿者中埃索美拉唑注射液/输注液的药代动力学、药效学和安全性:一项五交叉研究。
J Gastroenterol Hepatol. 2013 Dec;28(12):1823-8. doi: 10.1111/jgh.12305.
5
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.CYP2C19基因多态性对常规质子泵抑制剂剂量7天三联疗法根除幽门螺杆菌感染率的影响。
J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 1):1287-91. doi: 10.1111/j.1440-1746.2008.05392.x. Epub 2008 Jul 10.
6
Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.静脉注射40毫克埃索美拉唑与40毫克泮托拉唑对健康成年人24小时胃内pH值的影响。
Eur J Gastroenterol Hepatol. 2007 Feb;19(2):133-7. doi: 10.1097/01.meg.0000252628.57925.32.
7
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.埃索美拉唑一日两次给药较奥美拉唑、雷贝拉唑或兰索拉唑能更有效地抑制 CYP2C19 快速代谢者的胃酸分泌。
Aliment Pharmacol Ther. 2013 Nov;38(9):1129-37. doi: 10.1111/apt.12492. Epub 2013 Sep 16.
8
Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.从静脉注射泮托拉唑40mg/d治疗5天转换为口服埃索美拉唑40mg/d或泮托拉唑40mg/d治疗5天后的胃内酸度:一项针对健康成年志愿者的开放标签交叉研究。
Clin Ther. 2006 May;28(5):725-33. doi: 10.1016/j.clinthera.2006.05.001.
9
Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.静脉注射40毫克埃索美拉唑比静脉注射40毫克泮托拉唑能更快、更有效地控制胃内酸度:一项随机研究的结果。
Aliment Pharmacol Ther. 2004 Nov 15;20(10):1099-104. doi: 10.1111/j.1365-2036.2004.02272.x.
10
Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients.小剂量静脉注射泮托拉唑对韩国患者胃酸的最佳抑制作用
J Gastroenterol Hepatol. 2007 Sep;22(9):1429-34. doi: 10.1111/j.1440-1746.2007.05059.x. Epub 2007 Jul 20.

引用本文的文献

1
: High dose amoxicillin does not improve primary or secondary eradication rates in an Irish cohort.高剂量阿莫西林并不能提高爱尔兰队列中的初次或二次根除率。
World J Clin Cases. 2024 Jun 6;12(16):2773-2779. doi: 10.12998/wjcc.v12.i16.2773.
2
PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.采用生理药代动力学(PBPK)模型预测不同CYP2C19基因型中泮托拉唑的药代动力学。
Arch Pharm Res. 2024 Jan;47(1):82-94. doi: 10.1007/s12272-023-01478-7. Epub 2023 Dec 27.
3
A Pharmacogenetics-Based Approach to Managing Gastroesophageal Reflux Disease: Current Perspectives and Future Steps.
一种基于药物遗传学的胃食管反流病管理方法:当前观点与未来方向
Pharmgenomics Pers Med. 2023 Jun 23;16:645-664. doi: 10.2147/PGPM.S371994. eCollection 2023.
4
Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry.欧洲儿科患者幽门螺杆菌感染的管理:来自 EuroPedHp 注册研究的结果。
Infection. 2023 Aug;51(4):921-934. doi: 10.1007/s15010-022-01948-y. Epub 2022 Nov 3.
5
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.替戈拉赞与沃诺拉赞或埃索美拉唑相比对夜间胃酸的抑制作用。
Br J Clin Pharmacol. 2022 Jul;88(7):3288-3296. doi: 10.1111/bcp.15268. Epub 2022 Feb 23.
6
Type of proton-pump inhibitor and risk of iron deficiency in kidney transplant recipients - results from the TransplantLines Biobank and Cohort Study.质子泵抑制剂的类型与肾移植受者缺铁风险的关系——来自 TransplantLines 生物库和队列研究的结果。
Transpl Int. 2021 Nov;34(11):2305-2316. doi: 10.1111/tri.14110. Epub 2021 Oct 7.
7
Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions.利用药物遗传学概况丰富药物审查——一例他莫昔芬药物不良反应病例
Pharmgenomics Pers Med. 2021 Feb 19;14:279-286. doi: 10.2147/PGPM.S285807. eCollection 2021.
8
Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir.探索埃索美拉唑对胃和十二指肠液体积及利托那韦吸收的影响。
Pharmaceutics. 2020 Jul 17;12(7):670. doi: 10.3390/pharmaceutics12070670.
9
Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia.质子泵抑制剂对肺炎肝硬化患者死亡率的影响。
PLoS One. 2019 Apr 25;14(4):e0216041. doi: 10.1371/journal.pone.0216041. eCollection 2019.
10
Clinically relevant drug interactions with multikinase inhibitors: a review.多激酶抑制剂的临床相关药物相互作用:综述
Ther Adv Med Oncol. 2019 Jan 4;11:1758835918818347. doi: 10.1177/1758835918818347. eCollection 2019.